Cue Biopharma is trading at $21.99, up 12.37% in pre-market, with no confirmed company-specific news or overnight catalyst identified to explain the move.

  • Shares fell 20.48% to $19.57 on October 13; available evidence does not establish why they are rebounding.
  • Positive CUE-221 Phase 2 results and B. Riley Buy initiation were reported earlier, not as new October 14 developments.
  • Broader market indicators are modestly positive, but none show a same-direction move above 0.5%.